World Journal of Urology

, Volume 26, Issue 4, pp 359-364

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Lower urinary-tract symptoms and testosterone in elderly men

  • Aksam A. YassinAffiliated withInstitute of Urology and Andrology, Segeberger KlinikenGulf Medical University School of Medicine Email author 
  • , Ahmed I. El-SakkaAffiliated withDepartment of Urology, Suez Canal University, School of MedicineAl-Noor Specialist Hospital
  • , Farid SaadAffiliated withGulf Medical University School of MedicineBayer Schering Pharma, Scientific Affairs Men’s Healthcare
  • , Louis J. G. GoorenAffiliated withEndocrinology, VUMC



The objective was to examine the effects of testosterone administration on symptom scores of lower urinary tract symptoms (LUTS).


The literatures on the epidemiological association between the metabolic syndrome, erectile failure and (LUTS) were reviewed.


In men with the metabolic syndrome and erectile failure, often lower-than-normal testosterone levels are found. This is less clear for men with LUTS, but the relationship between testosterone and LUTS might be indirect and based on the association of the metabolic syndrome with an overactivity of autonomic nervous system. This overactivity may play a key role in increasing the severity of LUTS above an intrinsic basal intensity that is determined by the genitourinary factors in aging men. Androgen receptors are present in the epithelium of the urethra and the bladder. Testosterone may play a role in the reflex activity of the autonomic nervous system in the pelvis, or may interact with postsynaptic non-genomic receptors suppressing detrusor activity. Human neurons in the wall of the bladder contain nitric oxide synthase. Similar to the penis, testosterone has an impact on nitric oxide synthase.


Some studies investigating the effects of normalizing testosterone levels in elderly men have found a positive effect on variables of the metabolic syndrome and, simultaneously, on scores of the International Prostate Symptoms Score (IPSS) which is worthy of further investigation in randomized, controlled and sufficiently powered clinical trials.


Lower urinary-tract symptoms Aging Testosterone Phospho-diesterase type 5